+

WO1992013549A1 - Inhibition de la proliferation des cellules a l'aide de peptides hydrophobes - Google Patents

Inhibition de la proliferation des cellules a l'aide de peptides hydrophobes Download PDF

Info

Publication number
WO1992013549A1
WO1992013549A1 PCT/US1992/000905 US9200905W WO9213549A1 WO 1992013549 A1 WO1992013549 A1 WO 1992013549A1 US 9200905 W US9200905 W US 9200905W WO 9213549 A1 WO9213549 A1 WO 9213549A1
Authority
WO
WIPO (PCT)
Prior art keywords
leu
cells
cell proliferation
xaa
peptides
Prior art date
Application number
PCT/US1992/000905
Other languages
English (en)
Inventor
David R. Hathaway
Keith L. March
Original Assignee
Research Corporation Technologies, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Corporation Technologies, Inc. filed Critical Research Corporation Technologies, Inc.
Publication of WO1992013549A1 publication Critical patent/WO1992013549A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • Inappropriate, inopportune or excessive cell proliferation is a major cause not only of cancer but also of heart disease.
  • a cancerous cell loses 5 its ability to respond to cellular signals for growth restraint.
  • unchecked smooth muscle cell growth within the inner lining of arteries is a major cause of arteriosclerosis and of reocclusion after arterial dilation.
  • the present invention is directed towards the use of certain hydrophobic peptides to inhibit cellular growth, especially of smooth muscle cells and cancerous cells.
  • these hydrophobic peptides have 2-7 amino acids such as alanine (Ala), arginine (Arg),
  • cysteine Cys
  • isoleucine lie
  • leu leucine
  • One aspect of the present invention provides for the prevention and treatment of cancer by administrating the subject peptides to an animal. Another aspect of the present invention relates to 5 inhibiting cell proliferation of smooth muscle cells with the subject peptides. An additional aspect of this invention relates to the prevention of arterial occlusion in vivo using the subject peptides and methods of administration of these peptides for the prevention and
  • Cancer Intertwined with any discussion or study of cell proliferation is the nature and basis of cancer. This collection of undesirable diseases by definition involves cells which divide when they should not, thus producing tumors. Cancer can arise by changes in differentiated cell types, resulting in cancer cells that exhibit many of the morphological and functional characteristics of their respective non-cancerous precursor cells. Cancer is common in cells that normally undergo frequent division (e.g. epithelial cells of the skin) and so the problem may not be that cancer cells divide frequently but that they lack the normal control syterns to stop unwanted cell division. Hence, in an effort to find effective drugs for cancer therapy, reagents are sought which control or inhibit cell proliferation. The peptides of the present invention can provide this control.
  • arteriosclerosis is a disease of the inner lining, or intima, of arteries leading to formation of fatty lesions on the arterial inner surfaces.
  • arterio- sclerosis Almost half of all human beings die of arterio- sclerosis. Approximately two thirds of these deaths are caused by clot formation in a coronary artery, the remaining one third occur by clot formation, or hemorrhage of vessels, in other organs of the body, especially in the brain (causing strokes).
  • a commonly used treatment for coronary arterio ⁇ sclerosis is percutaneous transluminal coronary angioplasty, or arterial dilation. This procedure is a treatment of choice because it can enlarge a narrowed arterial passageway. However, arterial injury may occur during angioplasty and this injury can re-initiate or intensify the process of plaque formation leading to reocclusion of the artery.
  • reocclusion restenosis
  • restenosis restenosis
  • the process of restenosis is very similar to the formation of the original arteriosclerotic plague, but occurs on a shorter time scale.
  • Endothelial cell injury caused by angioplasty leads to platelet aggregation and shortly thereafter to activation of smooth-muscle cell proliferation.
  • Platelets secrete platelet-derived growth factor (PDGF), which is one of the most potent cell proliferative factors for smooth muscle cells found in serum.
  • PDGF platelet-derived growth factor
  • PDGF is also a chemotactic attractant for smooth muscle cells and may be responsible for attracting smooth muscle cells from the middle layer, or media, of the artery into the intima as well as for the initial proliferation of smooth muscle cells within the intima.
  • progression factors a second group of growth factors (termed "progression factors"), to initiate DNA synthesis and cell division.
  • PDGF alone appears to simply stimulate cells to enter a new cell cycle by causing the cell to move from the G Q arrest state to G.
  • Fig. 1 depicts the time course of a typical mammalian cell cycle). Exposure to progression factors allows cells to move through the cell cycle by initiating DNA synthesis (S phase). A number of progression factors are known, including epidermal growth factors from platelets and somatomedin-C present in serum.
  • specific peptides are shown to be effective in the inhibition of cell proliferation, and provide new reagents for the prevention and treatment of arteriosclerosis, prostatic hypertropy and various forms of cancer.
  • the block in cell division caused by the present peptides appears to occur prior to the S, or DNA synthesis, phase of the cell cycle.
  • a secondary block to cell division in the G ⁇ or M phase of the cell cycle, is also observed when cells are exposed to the subject peptides for longer periods of time.
  • the subject peptides are also inhibitors of calcium-dependent thiol proteases, calpains I and II.
  • the calpains are cytosolic cysteine proteases which are ubiquitously distributed in most cell types. The biological function of calpains is not clear. However, calpains have been implicated in numerous processes including the re-structuring of the plasma membrane (Zaidi, et al., 1989, J. Membrane Biol. ⁇ 10:209-216), the proteolysis of two important cytoskeletal proteins (Yoshida, et al., 1984, FEBS Letters 17 ⁇ :259-262) as well as the regulation of platelet aggregation (Fox, et al., 1983, J. Biol.
  • the present invention is directed to a method of inhibiting animal cell proliferation, especially the inappropriate, inopportune, or excessive cell proliferation associated with cancer, arteriosclerosis, restenosis, and smooth muscle or endothelial cells.
  • the method provides for administering a growth inhibiting amount of at least one of certain hydrophobic peptides to an animal or to cultured cells, wherein the subject pepties range from 2 to 7 amino acids and are represented by the formula:
  • R is hydrogen, epoxysuccinyl, cholesteryl, aryl, aralkyl or acyl
  • Xaa- and (Xaa) are independently Ala, Arg, lie. Leu, Lys, Met, nLeu, Phe, Pro, Thr, Tyr, Trp or Val; Xaa_ * is an amino acid from the group Ala, Arg,
  • Cys lie. Leu, Lys, nLeu, Phe, Pro, Thr, Tyr, Trp, Val or the corresponding alcohol, aldehyde, epoxysuccinate, acid
  • the preferred peptides of this invention include shorter peptides with two or three amino acids, i.e. m being 0 or 1, and more especially include benzyloxycarbonyl-Leu-norleucinal and acetyl-Leu-Leu- norleucinal.
  • the present method is useful in treating and preventing smooth muscle cell proliferation, arteriosclerosis, restenosis, especially restenosis occuring after percutaneous transluminal coronary angioplasty, and cancer and cancerous-like conditions such as prostatic hypertrophy, small cell carcinoma of the lung and some endotheliomas and sarcomas.
  • compositions containing the subject peptides with a pharmaceutically acceptable carrier for administration to an animal in accordance with the methods of this invention.
  • Fig. 1 depicts the phases of the mammalian cell cycle and the approximate duration of each phase.
  • Fig. 2 depicts the inhibitory effect of calpeptin (benzyloxycarbonyl-leucine-norleucinal) on the proliferation of vascular smooth muscle cells.
  • the open circles depict the growth of untreated cells; the solid circles depict the growth of cells treated with calpeptin.
  • Fig. 4 depicts a comparison of the amount of
  • DNA in cells exposed to calpeptin with that in cells not exposed to calpeptin.
  • This figure demonstrates that exposure to calpeptin arrests the division of most cells prior to DNA synthesis, since most cells exposed to calpeptin have a 2n content of DNA after 24 hours of culture in the presence of serum.
  • the top left panel provides a control of dividing cells for comparison with the other panels: a 2n DNA content is depicted by the left peak and a 4n DNA content is depicted by the right peak.
  • Chronic exposure of cells to calpeptin allows some progression through the cell cycle to the G- or M phase of the cell cycle as demonstrated by a higher DNA content in cells after 2 weeks exposure to calpeptin.
  • Fig. 5 depicts the effect that acetyl-Leu-Leu- norleucinal (Inhibitor I), acetyl-Leu-Leu-methioninal
  • the present invention provides a method of inhibiting cell proliferation in vivo or in vitro, using a class of hydrophobic peptides which are effective for that purpose.
  • a general formula depicting the structures of these peptides is:
  • R is hydrogen, an epoxysuccinyl, a cholesteryl, aryl, aralkyl or acyl;
  • Xaa, and Xaa are independently Ala, Arg, lie,
  • Xaa is an amino acid from the group Ala, Arg,
  • Cys lie. Leu, Lys, nLeu, Phe, Pro, Thr, Tyr, Trp, Val or the corresponding aldehyde, alcohol, epoxysuccinate, acid halide, carbonyl halomethane, or diazomethane derivative of the carboxy terminal amino acid.
  • Xaa,l is the N-terminal amino acid
  • Xaac is the
  • (Xaa) represents internal amino acids, if present.
  • the values of m range from 0 to 5, with preferred values of m being 0 to 3. The most preferred values for m are 0 or 1.
  • R is an acyl group it has the general formula R'-CO, wherein R' is a lower alkyl or aryl group.
  • R' is a lower alkyl or aryl group.
  • the term lower alkyl refers to alkyl groups containing one to six carbon atoms.
  • These groups may be straight-chained or branched and include such moieties as methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, t-butyl, pentyl, amyl, hexyl and the like.
  • the preferred alkyl groups are C--C. alkyl.
  • R or R' is an aryl group
  • aryl when used alone or in combination refers to an aromatic ring containing six to ten carbon atoms.
  • the present aryl groups include aralkyl groups (aryl groups with lower alkyl groups as ring substituents) and more specifically the groups benzyl, benzoyl, naphthyl, carboxybenzyl, benzyloxycarbonyl, or
  • n is an integer from 0-6 and preferably 0-3.
  • Aryl groups may have lower alkyl groups substituents at any, some or all, available ring positions. Lower alkyl group substituents are the same as those defined above.
  • Preferred R groups are cholesteryl, benzyloxycarbonyl, acetyl or benzoyl groups. The most -11-
  • R groups are acetyl, benzyloxycarbonyl and cholesteryl.
  • Xaa- the preferred amino acids are Arg, He, Leu, Lys, Met, nLeu, Phe, Tyr or Val. The most preferred are Leu nLeu or Val.
  • Each (Xaa) amino acid can independently be Ala, Arg, He, Leu, Lys, Met, nLeu, Phe, Pro, Tyr, Trp or Val.
  • Preferred Xaa amino acids are Arg, He, Leu, Lys, Met, nLeu, Phe, Thr, Trp, Tyr, or Val.
  • the most preferred (Xaa) amino acids are Leu, nLeu, or Val.
  • Preferred Xaa amino acids are the aldehyde, alcohol, epoxysuccinate, acid halide, carbonyl halomethane or diazomethane derivatives of Arg, He, Leu, Lys, nLeu, Phe, Thr, Trp, Tyr or Val.
  • the most preferred carboxy-terminal amino acids are the aldehyde derivatives of Leu, Lys, nLeu, Phe or Tyr.
  • the preferred hydrophobic peptides of this invention are calpeptin (benzyloxycarbonyl-Leu-norleucinal) and acetyl-Leu-Leu norleucinal.
  • the subject peptides may be chemically synthesized or isolated from a bacterial, fungal or plant source. Isolation can be by any technique used by one skilled in the art, including differential extraction, ion-exchange or gel filtration column chromatographic procedures and high pressure liquid chromatography. Chemical synthesis of the subject peptides is by any of the methods for peptide synthesis, for example by either solution or solid phase synthetic procedures such as the Merrifield procedure. Solid phase synthesis is commonly preferred for making longer peptides but many of the -12-
  • short peptides (with two to four amino acids) can be made efficiently by solution synthesis.
  • a basic problem in peptide synthesis is one of blocking or protecting the alpha amino group from indiscriminate reaction with a carboxyl group of an undesired amino acid; an additional problem is the prevention of reactions with amino acid side chains.
  • These undesirable side reactions are prevented by use of blocking groups that render an alpha amino group, or a side chain group, unreactive but permit the desired reaction to take place.
  • the blocking group In addition to providing protection against undesirable reactions, the blocking group must be easily removed without chemically altering the remainder of the molecule, especially the peptide linkage that has been built up during synthesis. (See generally, Morrison and Boyd, Organic Chemistry, Third Ed., Sec. 30.10 Synthesis of Peptides, pp. 1131-1133, 1983).
  • alpha amino protecting groups are tert-butyloxycarbonyl (Boc; cleaved by acid treatment), 9-fluorenylmethyloxycarbonyl (FMOC; removed by treatment with a secondary amine such as piperidine) and carbobenzyoxy (Z or Cbz; removed by catalytic hydrogenation) .
  • alpha-amino Boc, benzyl-based side chain protection strategy relies on the principle of graduated acid lability of the protecting groups. Boc-protected amino acids are inexpensive and available in high purity.
  • Boc-AA represents an amino acid with a Boc protecting group on its alpha amino group.
  • the subscript q on AA depicts the number of amino acids in the peptide; q is an integer, from 1-6 in the present
  • Tfa-0 is trifluoroacetic acid.
  • 0Bzl-CH 2 -C0-NH-CH 2 -Resin represents a possible coupling arm and its attachment to a solid phase resin. As described above, use of a solid phase resin is optional, depending on the size of the peptide.
  • the FMOC based strategy uses different mechanisms for removal of the alpha amino and side chain protecting groups: a secondary amine for the alpha amino protecting group and treatment with trifluoroacetic acid for the side chain protecting groups.
  • An FMOC-based peptide synthesis scheme is depicted below.
  • FMOC-AA An FMOC protected amino acid is represented by FMOC-AA.
  • the O-Bzl-O-CH j -Resin depicts an optional solid phase and its coupling arm to the synthetic peptide.
  • Synthesis of the present peptides need not be limited to the Boc and FMOC synthetic techniques depicted above.
  • benzyloxycarbonyl-leu-norleucinal (calpeptin) may be synthesized in solution, using benzyloxycarbonyl-leucine (Z-Leu-OH, 1 ) as starting material.
  • Z-Leu-OH is first reacted with isobutylchloroformate to make a mixed anhydride as depicted below.
  • the mixed anhydride ( 2 ) is then coupled with the methyl ester of norleucine (n-Leu-OMe, 3 ) using a coupling reagent, for example, N-ethyl-N' ,N'-dimethylaminopropyl carbodiimide (WSCD).
  • a coupling reagent for example, N-ethyl-N' ,N'-dimethylaminopropyl carbodiimide (WSCD).
  • the ester, Z-Leu-nLeu-OMe(_4) can be saponified by reaction with a strong base to form the acid (J5). Reduction with, for example sodium borohydride, yields the corresponding alcohol (j5) and subsequent partial oxidation with sulfur trioxide pyridine complex, triethylamine and dimethylsulfoxide, generates the corresponding aldehyde ( ) • These reactions are depicted below:
  • the above synthetic reactions illustrate general and specific techniques for synthesizing peptides, and for generating the aldehyde or alcohol derivatives from the C-terminal carboxylic acids.
  • Substituting the C-terminal carboxylic acid for diazomethane can be accomplished by first converting the carboxylate group into a mixed anhydride using, for example, isobutyl chloroformate in tetrahydrofuran and N-ethyl morpholine. This reaction mixture can then be added to ethereal diazomethane and allowed to react overnight. The diazomethane derivatized peptide may then -17-
  • Chloromethane derivatized peptides may be made from the diazomethane derivative by treatment of the later with HCl in ethanol at 0°C (Green et al., 1981, J. Biol. Chem. 256: 1923-1928; Sasaki, et al., 1986, J. Biochem. 99: 173-179).
  • the alpha amino group of the subject peptide may be amidated by addition of a R'-CO- group, e.g., a ⁇ yl group, or an epoxysuccinyl group. This can be done before, during or after peptide synthesis. Amidation may be accomplished by any of the art recognized procedures. For example, amide formation frequently involves acylation of the amine with acid chlorides, anhydrides, esters or carboxylic acids. The reaction with carboxylic acids may be of limited utility unless the acid is first activated so the -OH group becomes a good leaving group. Carbodiimides can be used to activate the carboxylic acid. Common acylating procedures for amide formation employ acid chlorides or anhydrides in pyridine.
  • cholesteryl or an aryl group is most easily done before the peptide is synthesized. This also prevents unwanted side reactions with non-N-terminal amino acid side groups.
  • Blocking groups may be used on the N-terminal amino acid side group and carboxylate, if needed.
  • the cholesteryl- or aryl-derivatized N-terminal amino acid may then be used directly in peptide synthesis. Cholesterol or any aryl group may be derivatized at a reactive position to provide a good leaving group.
  • the C-3 alchohol of cholesterol may be derivatized with p-toluenesulfonyl chloride (p-CH- j -CgH.-SO- j C-) , thionyl chloride (S0C1 2 ) or be replaced with a halide or other group to provide a leaving group.
  • p-CH- j -CgH.-SO- j C- p-CH- j -CgH.-SO- j C-
  • S0C1 2 thionyl chloride
  • Aryl groups with appropriate leaving groups are frequently commercially available.
  • the appropriately blocked amino acid is then reacted with the derivatized cholesterol or aryl group under conditions which allow the leaving group to be replaced by the N-terminal amine.
  • peptides may be purified and salts may be removed by gel electrophoresis, flash chromatography with a silica gel column, or by other size selective chromatography procedures, including gel chromatography or high-pressure liquid chromatography.
  • the present invention is directed to peptides of the instant general formulae which have utility to inhibit ndesired cellular growth. Hence these peptides are useful, for example, in the therapy or prevention of cancer, for prevention or treatment of arterial occlusion (arteriosclerosis) and for inhibiting smooth muscle or endothelial cell proliferation.
  • the present invention provides a method of inhibiting animal cell proliferation by administering an effective amount of at least one of the hydrophobic peptides defined in accordance with this invention.
  • An effective amount is that amount which is sufficient to inhibit cell growth or proliferation, particularly in cells which are in an inappropriate or excessive growth phase, or an amount to retard or prevent the course of a disease state.
  • the present method is useful for inhibiting cell proliferation whether it occurs in vivo or in vitro.
  • the method can include administering the subject peptides to an animal such as mammals, e.g. humans, monkeys, rabbits, mice, cows, or a veterinary animal or farm animal such as cats, dogs, chickens, turkeys, horses and the like.
  • in vitro cell proliferation is meant the inhibition of cultured cells, e.g. tissue culture cells or primary cell cultures obtained from a patient.
  • the method of inhibiting cultured cells can include administering, treating or co-culturing such cells in the presence of the subject peptide.
  • the peptides may be co-cultured with cells continuously or for varying periods of time.
  • the subject peptides can be administered singly or in combination as dictated by the exigency of the condition.
  • One skilled in the art can readily select and combine the subject peptides for simultaneous administration if necessary or as required by the circumstances of treatment.
  • the present method is particularly useful for inhibiting smooth muscle or endothelial cell proliferation. Consequently, this method provides a means of treating and preventing diseases associated with inappropriate, inopportune, or excessive cell proliferation of smooth muscle or endothelial tissues.
  • diseases include anteriosclerosis, restenosis and prostatic hypertrophy.
  • the treatment and prevention of restenosis by the present method is especially useful after percutaneous transluminal coronary angioplasty.
  • the present method is particularly useful for inhibiting the proliferation of cancerous cells in an animal or in cell culture.
  • the method provides a means of treating and preventing cancer and cancer-like diseases, e.g. benign tumors, arising from inappropriate, inopportune or excessive cell proliferation.
  • the administration of the subject peptides can be accomplished by any convenient route known to those skilled in the art by providing the subject peptides in an effective amount sufficient to inhibit cell proliferation as required by the exigency of the therapy. Routes of administration include oral, enteric, parenteral, intravenous, intramuscular, intrapericardial, intranasal and topical.
  • the amount of peptide delivered varies by route and can be determined by one skilled in the art in accordance with the guidelines provided herein, especially as relates to pharmaceutical compositions.
  • the present peptides inhibit cellular proliferation both in vitro and in vivo.
  • Cultured cells can be used to test for the effects of the present peptides on the rate of cell division.
  • the rate of cell division can be assessed by exposing cells to the subject peptides, then counting cell number as a function of time and comparing to controls. Addition of the subject peptides to the cell culture medium causes a significant decrease in cell growth. Cells grown without the subject peptides increase in number by almost 10-fold in four days. Cells grown in the presence of the subject peptides show little or no increase in number over a similar time period.
  • the rate of DNA synthesis can be determined by observing the incorporation of labeled nucleotide into cellular DNA.
  • a nucleotide may be radioactively labeled.
  • a labeled nucleotide may be a nucleotide analog that is readily incorporated into DNA and is detected by a second detector molecule.
  • a nucleotide analog is bromodeoxyuridine (BUdr) which may be detected by, for example, fluorescently labeled antibodies directed against bromodeoxyuridine.
  • BUdr bromodeoxyuridine
  • Total DNA content may be assessed, for example, by using propidium iodide.
  • cells may be synchronized or reversibly arrested in the G , or non-growing stage, of the cell cycle. Synchronization can be achieved by any of a number of reagents known to one skilled in the art, or simply by replacement of the culture medium with serum-free medium for 2 or more days. To initiate synchronized cell growth the cells may be rinsed with rich medium containing no cell cycle arresting reagent and then allowed to grow in normal, serum containing medium.
  • the peptides may be added to the growth medium at various times after removal of the cell cycle arresting reagent or after addition of serum to the medium, i.e., after releasing the cell cycle arrest. -22-
  • flow ⁇ ytometry can be used to sort cells on the basis of DNA content.
  • Cells which have incorporated more than a normal 2n amount of labeled or analog nucleotide can be distinguished, counted and sorted from cells with only a normal 2n DNA content.
  • DNA content is a reflection of a cell's stage in the cell cycle.
  • a 2n DNA content is the normal content for a cell which is not synthesizing DNA.
  • a cell with a 2n DNA content may be a non-growing cell, or a cell which has just divided but not yet begun DNA synthesis for another round of cell division.
  • a 4n DNA content indicates that the cell has finished duplicating its normal DNA content but has not yet physically divided into two daughter cells.
  • a DNA content between 2n and 4n indicates a cell is in the process of DNA synthesis.
  • Cells exposed to the subject peptides for short periods of time do not progress through the DNA synthesis (S) phase of the cell cycle and hence have a 2n DNA content long after cell cycle synchronization.
  • S DNA synthesis
  • some cells may undergo DNA synthesis (i.e., have a DNA content greater than 2n) but do not undergo cell division, indicating that the present peptides can cause a further block in the cycle at the G- or M phase.
  • the present invention demonstrates that transcription of two known cellular proto-oncogenes, c-fos and c-m c, are depressed relative to that observed in cells not exposed to the present peptides.
  • the present peptides are useful not only for depressing cell growth but also for depressing the production of factors that can lead to malignant cancer.
  • the active ingredients of the present pharmaceutical compositions include the present peptides which exhibit antiproliferative activity when administered in therapeutic amounts from about 0.1 mg to about 2000 mg per kg of body weight per day and preferably in amounts of from about 1.0 to 100 mg per kg of body weight. Localized administration of a 1.0 to 1000 micromolar solutions of the subject peptides is preferred.
  • One skilled in the art can adjust the dosage regimen to provide the optimum therapeutic response. For example, one daily dose may be administered or several divided doses may be given and the doses may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation.
  • the active compound may be administered in a convenient manner such as by an intravenous, intraparacardial, oral, intramuscular, intradermal, or subcutaneous route.
  • the active compounds may also be administered parenterally or intraperitoneally. Intravenous or intrapericardial administration is preferred.
  • the active ingredients of the subject pharmaceutical composition may be coated in a material to protect the ingredients from the action of enzymes, acids or other natural products.
  • Dispersions can be prepared in -24-
  • glycerol liquid polyethylene glycols, oils and in mixtures thereof. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms.
  • the pharmaceutical preparations suitable for injection include sterile liposomal suspensions, aqueous solutions or dispersions, as well as sterile powders for extemporaneous preparation of injectable solutions or dispersions. In all cases the preparation must be sterile and must be fluid to the extent that it is easily syringable. A preparation must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
  • the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • the prevention of microbial action can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it is preferable to include isotonic agents, for example, sugars or sodium chloride.
  • Preferred carriers are those which protect the active compound against rapid elimination from the body, such as controlled release formulations, including implants and microencapsulated delivery systems.
  • Biodegradable, biocompatible polymers can be used, such as polyanhydrides, polyglycolic acid, collagen and polylactic acid.
  • Liposomal carriers are also contemplated as preferred carriers by the present invention.
  • liposome carriers may incorporate within them agents which help target the subject peptides to the appropriate cell type, e.g. antibodies directed against membrane proteins found only on a specific cell type.
  • Liposomal formulations may be prepared by dissolving appropriate lipids in an inorganic solvent which is subsequently evaporated to generate a thin film of dried lipid on the surface of a container.
  • Appropriate lipids may include stearoyl phosphatidyl ethanolamine, stearoyl phosphatidyl choline, arachadoyl phosphatidyl choline and cholesterol.
  • aqueous solution of the active compound with the desired additional carriers or agents as described above, is then introduced into the container.
  • the container is then swirled to free the lipids from the sides of the container and to disperse lipid aggregates, thereby forming the liposomal suspension.
  • Methods for preparation of liposomal formuations will be apparent to those skilled in the art.
  • Sterile injectable solutions may also be prepared by incorporating the active compounds in the required amount and in the appropriate solvent with various of the other ingredients enumerated above, followed by filter sterilization.
  • dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients (enumerated above).
  • the preferred method of preparation is vacuum drying. This freeze-drying technique yields a powder of the active ingredient with any additional desired ingredients from the previously sterile-filtered solution.
  • the present peptides When the present peptides are suitably protected they may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or they may be enclosed in hard or soft gelatin capsule. They may also be compressed into tablets, or incorporated directly into a food which is part of the diet.
  • the active peptide may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
  • Such compositions and preparations should contain at least 1% of active compound.
  • the percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 5% to about 80% of the weight of the unit.
  • the amount of active compound in such therapeutically useful compositions is such that a suitable dosage is obtained.
  • Preferred compositions or preparations according to the present invention are prepared so that an oral unit dosage form contains between about 1 ⁇ g and 2000
  • the tablets, troches, pills, capsules and the like may also contain the following: a binder such as gum tragacanth, acacia, corn starch or gelatin; -27-
  • excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin may be added or a flavoring agent such as peppermint, oil or wintergreen, or cherry flavoring.
  • a liquid carrier such as a liquid carrier.
  • Various other materials may be present as coatings or to otherwise modify the physical form of the unit dosage. For instance, tablets, pills, or capsules may be coated with shellac.
  • a syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor.
  • sucrose as a sweetening agent
  • methyl and propylparabens as preservatives
  • a dye and flavoring such as cherry or orange flavor.
  • any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed.
  • the active compound may be incorporated into sustained-release preparations and formulations.
  • Unit dosage form refers to physically discrete units suitable as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • the specification for the novel dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active material and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active material for the prevention of disease in living subjects.
  • the principal active peptide ingredient is compounded for convenient and effective administration in pharmaceutically effective amounts with a suitable pharmaceutically acceptable carrier in dosage unit form as hereinbefore disclosed.
  • a unit dosage form can, for example, contain the principal active compound in amounts ranging from 1 ug to about 2000 mg. Expressed in proportions, the active compound is generally present in from about 1 ug to about 2000 per ml of carrier. In the case of compositions containing supplementary active ingredients, the dosages are determined by reference to the usual dose and manner of administration of the said ingredients.
  • pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like.
  • the use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
  • Bovine aortic smooth muscle cells were obtained by outgrowth from medial explants of thoracic aortae of cows within 4 hours of slaughter. Initial outgrowth as well as standard maintenance growth was in DMEM with 10% FBS added. Media were renewed every 2-3 days. All growth was in a humidified incubator equilibrated with a 5% C0 2 atmosphere. Cultures were passaged immediately prior to full confluence by brief exposure to HBSS (Hank's Balanced Salt Solution) containing trypsin (0.5 mg/ml) and EDTA (0.5 mM); all experiments were performed using cells of passage 7 or less.
  • HBSS Hort's Balanced Salt Solution
  • thymidine incorporation was used to assess cell growth. After obtaining cells as described above they were seeded in 24-well microtiter plates and allowed to attach overnight. The cultures were washed with PBS and placed in serum-free medium, consisting of DMEM with
  • Serum-free medium was then removed and replaced by DMEM with 10% FBS using concentrations of agent and carrier solutions identical to those in the serum-free medium.
  • 3 [ H] thymidine was added 18 hours after serum repletion to a concentration of 2 ⁇ Ci/ml, and was incubated for 6 additional hours. At the end of the incubation, cells were released from the wells and incorporated precursor removed by washing with distilled water. Cell residues were collected on glass mesh filter by a automated cell harvester. Radioactivity was measured by liquid scintillation spectroscopy. Flow Cytometric Assays Cells were plated, allowed to attach, and placed in serum free media for 48-52 hours as described above. Compounds to be tested were added at the designated concentrations in the serum-free media followed by serum-containing media, also as described above. At the specified times after serum addition, these cells were harvested by trypsin/EDTA, washed with -31-
  • RNAse RNAse to a final concentration of 2mg/ml.
  • Flow cytometric analyses were done using a Be ⁇ ton-Dickinson FACScan wherein the exciting wavelength was at 488 nm and the detecting wavelength at 585 nm. Events were gated on a fluorescence-area vs.-width map to eliminate potential clumped nuclei. Such events represented less than 3% of the total in general.
  • Calpeptin was synthesized using an adaptation of the protocol described by Tsujinaka et al. (1988, Bio ⁇ hem. Biophys. Res. Comm. 153:1201-1208). Briefly, Z-leu-OH was reacted with isobutyl chloroformate to form a mixed anhydride intermediate; this was then coupled to nLeu-OMe-HCl, followed by saponification with 1 N NaOH to yield Z-Leu-nLeu-OH. This was reduced to the alcohol with sodium borohydride, and then partially oxidized to the corresponding aldehyde with sulfur trioxide/pyridine.
  • the overall yield starting from the original components was 26% after purification by flash chromatography with a silica gel column using initially 20% then 30% ethyl acetate in hexanes mixture. Following recrystallization from hot hexanes, the melting point was 90-93°C. Purity was confirmed by TLC in 1:1 ethyl acetate:hexanes.
  • the Present Peptides are Antiproliferative Agents for Cells in Culture Cells were cultured as described in Example 1. To assess cell growth, either tritiated thymidine or a deoxynucleotide analog, bromodeoxyuridine (BUdr) was added to the medium; the incorporation of tritiated thymidine or of fluorescently labeled antibodies directed against bromodeoxyuridine, respectively, gave a measure of cell proliferation. Addition of propidium iodide to the medium allowed determination of the total amount of DNA. Cells were sorted by flow cytometry to distinguish populations of cells with different DNA (i.e., in this example, BUdr) contents.
  • BUdr bromodeoxyuridine
  • Fig. 3 Removal of serum from the medium was used to synchronize the cell cycle of cultured cells (Fig. 3), thereby allowing an assessment of which phase of the cell cycle was affected by the compounds tested.
  • cells normally require about 24 hr to progress through the cell cycle. After serum depletion almost all cells are arrested in the G-/G- phase with a 2n DNA content (a normal, non-dividing amount of DNA).
  • untreated cells exhibit little increase in DNA content at 12 hr after addition of serum. However, by 18 hr a significant number of untreated cells have more than a 2n DNA content, indicating that DNA synthesis is progressing.
  • Fig. 4 depicts the effect of calpeptin on the DNA content of cells.
  • calpeptin In the absence of calpeptin and 24 hr after serum addition to serum-depleted cells, more cells have a 4n DNA than a 2n DNA content, indicating that significant DNA synthesis is occurring in these cells.
  • cells exposed to calpeptin do not progress through the DNA synthesis phase of the cell cycle, as demonstrated by the 2n DNA content of almost all calpeptin exposed cells in Fig. 4.
  • By 2 weeks after serum addition most non-exposed cells have a 2n DNA content indicating that they have stopped growing.
  • Fig. 5 depicts the effects of different concentrations of calpeptin, acetyl-Leu-Leu-norleucinal (Inhibitor I of Fig. 5) and acetyl-Leu-Leu-methioninal (Inhibitor II of Fig. 5) on DNA synthesis in proliferating aortic smooth muscle cells as measured by tritiated thymidine incorporation by smooth muscle cells.
  • Cells exposed to either calpeptin or acetyl-Leu-Leu- norleucinal incorporate significantly less tritiated thymidine than do control cells or cells exposed to a synthetic peptide which is not an anti-proliferative agent (Inhibitor II) .
  • the Present Peptides Inhibit Transcription of Proto-Oncogenes
  • acetyl-leucine-leucine-norleucinal caused a 4-fold decrease, relative to controls, in the expression of c-fos and c-myc, known cellular proto-oncogenes.
  • a similar decrease in actin mRNA was observed upon addition of acetyl-leucine-leucine-norleucinal. In all cases, mRNA was obtained from the same number of cells.
  • APRT adenine phosphoribosyl- transferase
  • Acetyl-Leu-Leu-norleucinal has been shown to 5 reduce proliferation of cells in culture (Example 2).
  • arteriosclerotic rabbits were treated with acetyl-Leu-Leu- norleucinal immediately after angioplasty.
  • Prevention of restenosis after angioplasty was used as a test system for prevention of arteriosclerosis because the underlying mechanisms of restenosis are like those occurring during arteriosclerotic plaque formation.
  • Angiography showed that the luminal diameter of animals treated with acetyl-Leu-Leu-norleucinal was larger than in controls, i.e. there was a smaller decrease after angioplasty in treated than in non-treated animals.
  • Neointimal area was the same for all groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un procédé d'utilisation de certains peptides hydrophobes pour l'inhibition de la prolifération des cellules, les peptides en question ayant la formule générale suivante: R-Xaa1-(Xaa)m-Xaac. Les peptides en question ont de 2 à 7 acides aminés tels que l'alanine (Ala), l'arginine (Arg), la cystéine (Cys), l'isoleucine (Ile), la leucine (Leu), la lysine (Lys), la méthionine (Met), la norleucine (nLeu), la phénylalanine (Phe), la proline (Pro), la thréonine (Thr), la tyrosine (Tyr), le tryptophan (Trp), ou la valine (Val). Selon la présente invention ces peptides sont des inhibiteurs puissants de la prolifération de cellules ainsi que des inhibiteurs de la synthèse de deux proto-oncogènes cellulaires. Un aspect de la présente invention concerne la prévention et le traitement du cancer en administrant ces peptides. Un autre aspect de la présente invention concerne l'inhibition de la prolifération des cellules en utilisant les peptides en question dans le traitement et la prévention de l'hypertrophie prostatique, l'occlusion artérielle (resténose), l'artériosclérose, et les maladies des cellules des muscles lisses.
PCT/US1992/000905 1991-02-07 1992-02-04 Inhibition de la proliferation des cellules a l'aide de peptides hydrophobes WO1992013549A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65216191A 1991-02-07 1991-02-07
US652,161 1991-02-07

Publications (1)

Publication Number Publication Date
WO1992013549A1 true WO1992013549A1 (fr) 1992-08-20

Family

ID=24615749

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/000905 WO1992013549A1 (fr) 1991-02-07 1992-02-04 Inhibition de la proliferation des cellules a l'aide de peptides hydrophobes

Country Status (1)

Country Link
WO (1) WO1992013549A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0750507A1 (fr) * 1994-03-18 1997-01-02 The President And Fellows Of Harvard College REGULATION DE L'ACTIVITE DE NF-$g(k)B PAR LE PROTEASOME
WO2003080182A1 (fr) * 2001-03-26 2003-10-02 Abbott Gmbh & Co. Kg Utilisation d'inhibiteurs de la cysteine protease pour le traitement de maladies pulmonaires
US7122524B2 (en) * 2001-02-05 2006-10-17 Neurotell Ag Tripeptides and tripeptide derivatives for the treatment of postlesional disease of the nervous system
US7129213B2 (en) * 2001-02-05 2006-10-31 Neurotell Ag Tripeptides and tripeptide derivatives for the treatment of neurodegenerative diseases
US7163922B2 (en) * 2001-02-05 2007-01-16 Neurotell Ag Tripeptide derivatives for the treatment of postlesional diseases of the nervous system
US8232243B2 (en) 1999-12-02 2012-07-31 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Tyrosine- and tryptophan-containing peptides as antioxidants
US9856288B2 (en) * 2014-03-30 2018-01-02 Zhejiang University Tripeptide epoxyketone compound constructed by heterocycle and preparation method and use thereof
US10590084B2 (en) 2016-03-09 2020-03-17 Blade Therapeutics, Inc. Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof
US10934261B2 (en) 2016-09-28 2021-03-02 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
US11292801B2 (en) 2016-07-05 2022-04-05 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61103897A (ja) * 1984-10-26 1986-05-22 Suntory Ltd 抗カルパインの製造法
US4752602A (en) * 1985-09-09 1988-06-21 Board Of Regents, The University Of Texas System Dipeptide alkyl esters and their uses
EP0383190A2 (fr) * 1989-02-17 1990-08-22 Bio-Mega/Boehringer Ingelheim Research Inc. Inhibiteur de la ribonucléotide réductase

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61103897A (ja) * 1984-10-26 1986-05-22 Suntory Ltd 抗カルパインの製造法
US4752602A (en) * 1985-09-09 1988-06-21 Board Of Regents, The University Of Texas System Dipeptide alkyl esters and their uses
EP0383190A2 (fr) * 1989-02-17 1990-08-22 Bio-Mega/Boehringer Ingelheim Research Inc. Inhibiteur de la ribonucléotide réductase

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, Volume 153, No. 3, issued 30 June 1988, TSUJINAKA et al., "Synthesis of A New Cell Penetrating Calpain Inhibitor (Calpeptin)", pages 1201-1208. *
BLOOD, Volume 76, No. 12, issued 15 December 1990, FOX et al., "The Role of Calpain in Stimulus-Response Coupling: Evidence that Calpain Mediates Agonist-Induced Expression of Procagulant Activity in Platelets", pages 2510-2519. *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0750507A1 (fr) * 1994-03-18 1997-01-02 The President And Fellows Of Harvard College REGULATION DE L'ACTIVITE DE NF-$g(k)B PAR LE PROTEASOME
EP0750507A4 (fr) * 1994-03-18 1999-03-31 Harvard College REGULATION DE L'ACTIVITE DE NF--g(k)B PAR LE PROTEASOME
US8232243B2 (en) 1999-12-02 2012-07-31 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Tyrosine- and tryptophan-containing peptides as antioxidants
US7122524B2 (en) * 2001-02-05 2006-10-17 Neurotell Ag Tripeptides and tripeptide derivatives for the treatment of postlesional disease of the nervous system
US7129213B2 (en) * 2001-02-05 2006-10-31 Neurotell Ag Tripeptides and tripeptide derivatives for the treatment of neurodegenerative diseases
US7163922B2 (en) * 2001-02-05 2007-01-16 Neurotell Ag Tripeptide derivatives for the treatment of postlesional diseases of the nervous system
WO2003080182A1 (fr) * 2001-03-26 2003-10-02 Abbott Gmbh & Co. Kg Utilisation d'inhibiteurs de la cysteine protease pour le traitement de maladies pulmonaires
US9856288B2 (en) * 2014-03-30 2018-01-02 Zhejiang University Tripeptide epoxyketone compound constructed by heterocycle and preparation method and use thereof
US10590084B2 (en) 2016-03-09 2020-03-17 Blade Therapeutics, Inc. Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof
US11292801B2 (en) 2016-07-05 2022-04-05 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
US10934261B2 (en) 2016-09-28 2021-03-02 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
US11339130B1 (en) 2016-09-28 2022-05-24 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof

Similar Documents

Publication Publication Date Title
EP2402369B1 (fr) Fragments de peptides pour induire la synthèse de protéines de matrice extracellulaire
JP4537581B2 (ja) ＶＩＩａ因子阻害剤
CA2786280A1 (fr) Methodes de prevention ou de traitement d'une lesion d'occlusion de vaisseau
EP2552470B1 (fr) Peptides pour favoriser l'angiogenèse et leur utilisation
JPH05504336A (ja) ペプチド誘導体，その製法，これを含む医薬品及び緑内障の治療法
CN101199503A (zh) Hif羟化酶抑制剂
CZ287816B6 (en) Peptide, process of its preparation, pharmaceutical preparation in which it is comprised and use thereof
BG65065B1 (bg) Пептидни антиангиогенни лекарствени средства
JPH0364514B2 (fr)
US7053046B2 (en) Peptide activators of VEGF
WO1992013549A1 (fr) Inhibition de la proliferation des cellules a l'aide de peptides hydrophobes
US4987122A (en) Peptide compounds and medical method of use thereof
RU2079509C1 (ru) Производные пептидов, обладающие способностью регулировать пролиферацию клеток, и способы ингибирования клеточной пролиферации человека и животного (варианты)
JPH06510787A (ja) 筋内膜増殖の治療または予防用のナトリウム排泄増加性ペプチドまたは中性エンドペプチターゼ阻害剤を含む薬剤組成物
US20030171298A1 (en) Retroinverso polypeptides that mimic or inhibit thrombospondin
EP0397635A1 (fr) Peptide avec une activité antimétastatique
WO2001094382A1 (fr) Oligopeptides
RU2380371C2 (ru) Низкомолекулярные производные пептидов как ингибиторы взаимодействия ламинина/нидогена
AU721261B2 (en) Peptide inhibitors of hematopoietic cell proliferation
JPH0796557B2 (ja) 新規ペプチド、その製法およびそれを含有する医薬組成物
EP0474456A2 (fr) Oligopeptides ayant une activité sélective d'inhibition de la prolifération des cellules hémopoiétiques
Kasafírek et al. Two-step generation of spirocyclic dipeptides from linear peptide ethyl ester precursors
EP0372410B1 (fr) Utilisation des amides héterocycliques pour inhibiter la métastase d'une tumeur
JP2003089700A (ja) ペプチド
JP2004513059A (ja) ペプチド産物、方法及び組成物

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

COP Corrected version of pamphlet

Free format text: PAGES 1/5-5/5,DRAWINGS,REPLACED BY NEW PAGES 1/6-6/6;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载